Bringing Sustainability and Strategy together to create Shared Value: Insights from Chiesi’s 2023 Sustainability Report
22 Luglio 2024
Oak Hill Bio and Chiesi Group Announce First Patient Enrolled in the Resumed Phase 2b Clinical Study Evaluating OHB-607 for the Prevention of Bronchopulmonary Dysplasia, the Most Common Cause of Chronic Lung Disease in Premature Infants
17 Maggio 2024
Chiesi Group Forges Alliance with Karolinska Institutet to Tackle Urgent Health Challenges
14 Maggio 2024
Chiesi and Gossamer Bio Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications
Chiesi Carbon Minimal Inhalers reach new milestone with clinical phase III initiation
03 Aprile 2024
Chiesi Group: a new supplementary labor agreement in Italy puts people and their needs first
18 Marzo 2024
Chiesi Group announces the passing of Honorary President Dr. Paolo Chiesi (1940-2024)
05 Marzo 2024
PAST, PRESENT, FUTURE
15 Febbraio 2024
Chiesi Group and Oak Hill Bio announce License and Development Agreement to develop, manufacture, and commercialize OHB-607, a potentially transformative neonatal therapy
